STL Index for: biologics

Alefacept Treatment for Chronic Plaque Psoriasis

Biologic agents were introduced during the past decade as a new class of treatments for chronic psoriasis. This review will discuss data from clinical trials that have provided new insights into the efficacy, safety, and cost effectiveness of alefacept as a treatment for psoriasis.

Update on Drugs and Drug News – June 2008

Update on Calcipotriene 0.005% + Betamethasone Dipropionate 0.064% Topical Suspension (Taclonex Scalp®), Calcipotriene 0.005% Topical Solution, and Botulinum Toxin Type A (Reloxin®) and news about new drugs for acne and psoriasis.

Update on Drugs and Drug News – May 2008

Update on Triphendiol (formerly NV-196), Cyclic pentapeptide vascular-targeting agent ADH-1, Certolizumab pegol Cimzia® and drug news from around the world.

Systemic and Light Therapies for the Management of Childhood Psoriasis: Part II

The choice of treatment for psoriasis in children, as in adults, is determined by disease acuity, morphology, distribution, and severity. Part II of this 2-part series features an overview of systemic and light therapies including their varying degrees of effectiveness, potential side-effects and applications in clinical practice.

Biologic Drugs and How They Work

Biologics represent a new type of treatment that shows promise. This article provides a quick overview of how they work, and what makes these classes of drugs promising.

TNF-a Inhibitors in Dermatology

To date, the US FDA has approved three tumor necrosis factor (TNF)-a inhibitors for use in dermatology. The distinct and targeted mechanism of action of the TNF inhibitors allows dermatologists to customize therapy to match the individual needs and characteristics of patients who are candidates for systemic therapy.

Update on Drugs and Drug News – July-August 2007

Update on Hyaluronic Acid Gel Particles PERLANE®, Cervical Cancer Vaccine Cervarix®, Vaccinia Immune Globulin Intravenous (Human), Levocetirizine Dihydrochloride Xyzal®, and Infliximab Remicade®.

A Review of Biologic Treatments for Psoriasis with Emphasis on Infliximab

Moderate-to-severe psoriasis is known to affect millions of people around the globe. This chronic disease substantially impacts patients by impairing their quality of life. The biologics are the newest and most effective therapeutic weapon in the treatment of moderate-to-severe psoriasis and psoriatic arthritis.

Amevive® (Alefacept) Introduction

Amevive® (Alefacept) and its clinical experience, and clinical evidence are discussed. As a biologic, safety profiles, and mechanisms of action are also covered.

New Systemic Treatments for Psoriasis

Biologics are one of the more effective and relatively safe options for long-term control of psoriasis. They have reduced the time needed to clear the signs of chronic disease, and are effective in maintaining a disease-free state for longer durations. Biologics can safely be used with other treatment modalities (i.e., methotrexate, cyclosporine, acitretin and hydroxyurea).

Etanercept for the Treatment of Psoriasis

Etanercept has recently been approved for the treatment of moderate-to-severe plaque psoriasis at a dose of 50mg twice per week for 12 weeks followed by a maintenance dose of 50mg once weekly thereafter. Clinical studies have shown excellent efficacy and a good safety profile in patients with psoriasis.

Update on Drugs & Drug News, December 2005 – January 2006

Updates on: Efalizumab RAPTIVA®Adalimumab HUMIRA®Infliximab REMICADE®Diphtheria, Tetanus, Pertussis, Polio, Hemophilus Influenza Type b Vaccine PENTACEL™ Mupriocin Ointment 2%

Etanercept, a TNF Antagonist for Treatment of Psoriatic Arthritis and Psoriasis

Etanercept (Enbrel®, Amgen and Wyeth), a tumor necrosis factor (TNF) antagonist, was approved in January 2002, for the treatment of psoriatic arthritis (PsA). Etanercept was evaluated for the treatment of PsA and psoriasis in a preliminary study of 60 patients and in a confirmatory phase III study of 205 patients.

The Use Of Interleukins For Advanced Melanoma

Treatment of metastatic melanoma using traditional chemotherapy regimens has been disappointing. However, recent work with agents that modify the host’s immune system (e.g., interleukins) have provided limited but encouraging results. Interleukins are a group of molecules involved in immune cell signaling.